Direct answer: No human trial was found that establishes the safety, interaction profile, dose, or benefit of combining MOTS-c with tirzepatide. MOTS-c remains investigational. Its current phase 2a study compares MOTS-c with placebo, not tirzepatide, so “no known interaction” is not evidence that the stack is compatible.
Evidence status at a glance
| Question | Best-supported answer |
|---|---|
| Is MOTS-c FDA approved? | No approved prescribing information or indication was identified |
| Has the combination been tested in people? | No registered human combination study was found |
| Is there a validated stack schedule? | No |
| Do different mechanisms prove compatibility? | No; mechanism does not replace interaction and safety data |
What the registered MOTS-c trial tests
ClinicalTrials.gov lists a recruiting phase 2a randomized, double-blind, placebo-controlled study in adults with prediabetes and overweight or obesity. The record describes subcutaneous MOTS-c or placebo once daily for 12 weeks.
There is no tirzepatide arm. The study cannot establish whether adding MOTS-c to Mounjaro or Zepbound improves weight loss, insulin sensitivity, exercise capacity, or any other outcome, and it cannot quantify combination-specific adverse effects.
Why “no known interaction” is not enough
An investigational compound may have no listed interaction because the necessary studies and postmarketing surveillance do not exist. Absence of a listing is not a negative interaction study. Tirzepatide can cause gastrointestinal adverse effects and changes in glucose, while the human effects, product quality, and interaction profile of non-approved MOTS-c products remain uncertain.
From the FormBlends catalog
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →What current tirzepatide labeling contributes
Zepbound labeling provides tested dosing, contraindications, warnings, adverse reactions, and interaction considerations for the approved product. It does not provide a MOTS-c protocol. Staggering two agents may make a reaction easier to attribute, but it does not validate an unapproved agent or make the combination evidence-based.
Frequently asked questions
Can MOTS-c and tirzepatide be taken together?
There is not enough human evidence to establish that the combination is safe or beneficial.
Do independent mechanisms reduce interaction risk?
Not necessarily. Theory cannot substitute for dose-finding, interaction, and adverse-event data.
Does MOTS-c improve tirzepatide weight loss?
No human trial identified here establishes additional weight loss from combining them.
Is there a tested stack dose?
No validated combination dose or injection protocol was identified.
Primary sources
Evidence review completed July 31, 2026. The registry search result can change as new trials are added.
Ready when you are
MOTS-c
Mitochondrial-derived exercise mimetic that regulates metabolic homeostasis · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View MOTS-c →